A reversal strategy of disease using the most up to date current therapy, macitentan, would be utilised using the most relevant contemporary model of PH, the SUGEN / hypoxia model. This will be the first study to correlate non-invasive myocardial tissue characterisation by means of T1 mapping with histological analysis in subjects with pulmonary hypertension using a disease targeted therapy.
|Effective start/end date
|1/06/19 → 31/12/22
- Actelion Pharmaceuticals Ltd.: £38,469.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.